Neuroprotective effect of treatment with galantamine and choline alphoscerate on brain microanatomy in spontaneously hypertensive rats

Journal of the Neurological Sciences

Volumn 283, Issue 1-2, 2009, Pages 187-194

  Tayebati, Seyed Khosrow ^a   Di Tullio, Maria Antonietta ^a   Tomassoni, Daniele ^a   Amenta, Francesco ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Cholinergic precursors; Cholinesterase inhibitors; Neuroprotection; Spontaneously hypertensive rats; Vascular dementia

Indexed keywords

AQUAPORIN 4; CHOLINE ALFOSCERATE; CHOLINESTERASE INHIBITOR; GALANTAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CHOLINERGIC SYSTEM; CHOLINESTERASE INHIBITION; CONTROLLED STUDY; DENTATE GYRUS; DRUG EFFECT; FRONTAL CORTEX; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; MULTIINFARCT DEMENTIA; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; AQUAPORIN 4; ASTROCYTES; BRAIN; CELL DEATH; DENTATE GYRUS; FRONTAL LOBE; GALANTAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; GLYCERYLPHOSPHORYLCHOLINE; HIPPOCAMPUS; HYPERTENSION; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NEUROFILAMENT PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 67650146159     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2009.02.349     Document Type: Article

References (40)

1. Erkinjuntti T., Román G., Gauthier S., Feldman H., and Rockwood K. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 35 (2004) 1010-1017
2. Knopman D., Parisi J., Boeve B.F., et al. Vascular dementia in a population-based autopsy study. Arch Neurol 60 (2003) 569-575
3. Román G.C. Vascular dementia: distinguishing characteristics, treatment, and prevention. J Am Geriatr Soc 51 (2003) S296-S304
4. Everitt B.J., and Robbins T.W. Central cholinergic systems and cognition. Annu Rev Psychol 48 (1997) 649-684
5. Brashear H.R. Galantamine in the treatment of vascular dementia. Int Psychogeriatr 15 (2003) 187-193
6. Kavirajan H., and Schneider L.S. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 6 (2007) 782-792
7. Sobrado M., Roda J.M., López M.G., Egea J., and García A.G. Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation. Neurosci Lett 365 (2004) 132-136
8. Arias E., Alés E., Gabilan N.H., Cano-Abad M.F., Villarroya M., García A.G., et al. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology 46 (2004) 103-114
9. Arias E., Gallego-Sandín S., Villarroya M., García A.G., and López M.G. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther 315 (2005 Dec) 1346-1353
10. Kume T., Sugimoto M., Takada Y., Yamaguchi T., Yonezawa A., Katsuki H., et al. Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons. Eur J Pharmacol 527 (2005) 77-85
11. Geerts H. Indicators of neuroprotection with galantamine. Brain Res Bul 64 (2005) 519-524
12. Van Dam D., and De Deyn P.P. Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Eur Neuropsychopharmacol 16 (2006) 59-69
13. Francis P.T., Nordberg A., and Arnold S.E. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease?. Trends Pharmacol Sci 26 (2005) 104-111
14. Amenta F., Parnetti L., Gallai V., and Wallin A. Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?. Mech Ageing Dev 122 (2001) 2025-2040
15. Parnetti L., Amenta F., and Gallai V. Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data. Mech Ageing Dev 122 (2001) 2041-2055
16. Amenta F., Tayebati S.K., Vitali D., and Di Tullio M.A. Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission. Mech Ageing Dev 127 (2006) 173-179
17. Parnetti L., Mignini F., Tomassoni D., Traini E., and Amenta F. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?. J Neurol Sci 257 (2007) 264-269
18. Sabbatini M., Strocchi P., Vitaioli L., and Amenta F. The hippocampus in spontaneously hypertensive rats: a quantitative microanatomical study. Neuroscience 100 (2000) 251-258
19. Sabbatini M., Tomassoni D., and Amenta F. Hypertensive brain damage: comparative evaluation of protective effect of treatment with dihydropyridine derivatives in spontaneously hypertensive rats. Mech Ageing Dev 122 (2001) 2085-2105
20. Mori E., Hashimoto M., Krishnan K.R., and Doraiswamy P.M. What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors?. Alzheimer Dis Assoc Disord 20 (2006) S19-26
21. Lipton S.A. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov 5 (2006) 160-170
22. Parsons C.G., Stöffler A., and Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 53 (2007) 699-723
23. Akaike A. Preclinical evidence of neuroprotection by cholinesterase inhibitors. Alzheimer Dis Assoc Disord 20 (2006) S8-11
24. Gattu M., Pauly J.R., Boss K.L., Summers J.B., and Buccafusco J.J. Cognitive impairment in spontaneously hypertensive rats: role of central nicotinic receptors. I. Brain Res 771 (1997) 89-103
25. Gattu M., Terry Jr. A.V., Pauly J.R., and Buccafusco J.J. Cognitive impairment in spontaneously hypertensive rats: role of central nicotinic receptors. Part II. Brain Res 771 (1997) 104-114
26. Ferrari R., Frasoldati A., Leo G., Torri C., Zini I., Agnati L.F., et al. Changes in nicotinic acetylcholine receptor subunit mRNAs and nicotinic binding in spontaneously hypertensive stroke prone rats. Neurosci Lett 277 (1999) 169-172
27. Terry Jr. A.V., Hernandez C.M., Buccafusco J.J., and Gattu M. Deficits in spatial learning and nicotinic-acetylcholine receptors in older, spontaneously hypertensive rats. Neuroscience 101 (2000) 357-368
28. Hernandez C.M., Høifødt H., and Terry Jr. A.V. Spontaneously hypertensive rats: further evaluation of age-related memory performance and cholinergic marker expression. J Psychiatry Neurosci 28 (2003) 197-209
29. Hohnadel E.J., Hernandez C.M., Gearhart D.A., and Terry Jr. A.V. Effect of repeated nicotine exposure on high-affinity nicotinic acetylcholine receptor density in spontaneously hypertensive rats. Neurosci Lett 382 (2005) 158-163
30. Woodruff-Pak D.S., and Gould T.J. Neuronal nicotinic acetylcholine receptors: involvement in Alzheimer's disease and schizophrenia. Behav Cogn Neurosci Rev 1 (2002) 5-20
31. Picciotto M.R., and Zoli M. Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease. Front Biosci 13 (2008) 492-504
32. Prendergast M.A., Self R.l., Smith K.J., Ghayoumi L., Mullins M.M., Butler T.R., et al. Microtubule-associated targets in chlorpyrifos oxon hippocampal neurotoxicity. Neuroscience 146 (2007) 330-339
33. Sigala S., Imperato A., Rizzonelli P., Casolini P., Missale C., and Spano P. l-alpha-glycerylphosphorylcholine antagonizes scopolamine-induced amnesia and enhances hippocampal cholinergic transmission in the rat. Eur J Pharmacol 211 (1992) 351-358
34. Amenta F., Franch F., Ricci A., and Vega J.A. Cholinergic neurotransmission in the hippocampus of aged rats: influence of l-alpha-glycerylphosphorylcholine treatment. Ann N Y Acad Sci 695 (1993) 311-313
35. Parnetti L., Abate G., Bartorelli L., Cucinotta D., Cuzzupoli M., Maggioni M., et al. Multicentre study of l-alpha-glyceryl-phosphorylcholine vs ST200 among patients with probable senile dementia of Alzheimer's type. Drugs Aging 3 (1993) 159-164
36. Amenta F., Liu A., Zeng Y.C., and Zaccheo D. Muscarinic cholinergic receptors in the hippocampus of aged rats: influence of choline alphoscerate treatment. Mech Ageing Dev 76 (1994) 49-64
37. Barbagallo Sangiorgi G., Barbagallo M., Giordano M., Meli M., and Panzarasa R. alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Ann N Y Acad Sci 717 (1994) 253-269
38. Muccioli G., Raso G.M., Ghé C., and Di Carlo R. Effect of l-alpha glycerylphosphorylcholine on muscarinic receptors and membrane microviscosity of aged rat brain. Prog Neuropsychopharmacol Biol Psychiatry 20 (1996) 323-339
39. Tomassoni D., Avola R., Mignini F., Parnetti L., and Amenta F. Effect of treatment with choline alphoscerate on hippocampus microanatomy and glial reaction in spontaneously hypertensive rats. Brain Res 1120 (2006) 183-190
40. Sabbatini M., Catalani A., Consoli C., Marletta N., Tomassoni D., and Avola R. The hippocampus in spontaneously hypertensive rats: an animal model of vascular dementia?. Mech Ageing Dev 123 (2002) 547-559